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Charcot–Marie–Tooth disease type 2A is an autosomal dominant axonal form of peripheral neuropathy caused by mutations in
the mitofusin 2 gene. Mitofusin 2 encodes a mitochondrial outer membrane protein that participates in mitochondrial fusion in
mammalian cells. How mutations in this protein lead to Charcot–Marie–Tooth disease type 2A pathophysiology remains unclear.
We have generated a transgenic mouse expressing either a mutated (R94Q) or wild-type form of human mitofusin 2 in neurons
to evaluate whether the R94Q mutation was sufficient for inducing a Charcot–Marie–Tooth disease type 2A phenotype. Only
mice expressing mitofusin 2R94Q developed locomotor impairments and gait defects thus mimicking the Charcot–Marie–Tooth
disease type 2A neuropathy. In these animals, the number of mitochondria per axon was significantly increased in the distal part
of the sciatic nerve axons with a diameter smaller than 3.5km. Importantly, the analysis of R94Q transgenic animals also
revealed an age-related shift in the size of myelinated axons leading to an over-representation of axons smaller than 3.5 km.
Together these data suggest a link between an increased number of mitochondria in axons and a shift in axonal size distribution
in mitofusin 2R94Q transgenic animals that may contribute to their neurological phenotype.
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Introduction
With an estimated prevalence of 1 in 2500 individuals, Charcot–
Marie–Tooth (CMT) neuropathies (also called hereditary motor
and sensory neuropathies) are among the most common inherited
neurological disorders (Skre, 1974). CMT disease type 2A
(CMT2A) is the axonal form of CMT disease, with clinical symp-
toms including progressive distal limb muscle weakness and atro-
phy, distal sensory loss and mobility impairment, which often lead
to wheelchair dependency. A degeneration of the long peripheral
axons appears to be the major event leading to the disorder es-
pecially in early onset symptomatic patients. In contrast, late onset
symptomatic patients have been shown to present no detectable
signs of axonal degeneration (Schro¨der, 2001; Chung et al.,
2006). Recently, a major advance in the comprehension of the
disease has been reached when several studies identified muta-
tions in the mitofusin 2 gene (MFN2) as responsible for CMT2A
(Zuchner et al., 2004; Kijima et al., 2005; Chung et al., 2006;
Verhoeven et al., 2006). MFN2 is a highly conserved large
GTPase protein anchored in the outer mitochondrial membrane.
Together with mitofusin 1 (MFN1), MFN2 plays a role in the
fusion of the outer mitochondrial membrane in mammalian cells
(for review, see Chan, 2006) through the formation of homo
and/or hetero complexes (Detmer and Chan, 2007a). MFN1 and
2 are essential proteins since their inactivation in mice leads to
mid-gestation lethality at E12.5 and E11.5, respectively (Chen
et al., 2003). Moreover, conditional deletion of only Mfn2 is
sufficient to cause degeneration of Purkinje cells in the cerebellum
(Chen et al., 2007). The cause for the degeneration of these cells
is not yet clearly established. So far only a few studies have ad-
dressed the role of MFN2 mutations as the cause of CMT2A neur-
opathy. Motoneuron specific overexpression of the MFN2T105M
mutated form leads to a severe and general axonal loss of moto-
neurons exclusively in young homozygote transgenic animals
(Detmer et al., 2008). However, unlike in patients where mito-
chondria tend to accumulate in axons (Verhoeven et al., 2006;
Vallat et al., 2008; Funalot et al., 2009) the mitochondria aggre-
gate around the nucleus and are absent from axons of moto-
neurons in T105M transgenic mice. Similar data were obtained
when MFN2 proteins with mutations found in CMT2A disease
were overexpressed in cultured rat neurons from dorsal root gan-
glion (Baloh et al., 2007). While potentially interesting, the rele-
vance of MFN2-induced perinuclear mitochondrial aggregation for
the pathophysiology of CMT2A disease is difficult to interpret
since this phenomenon has been observed when the level of
MFN2 overexpression was high (Eura et al., 2003; Detmer and
Chan, 2007b).
To investigate the role of MFN2 mutations in the physiopathol-
ogy of CMT2A further, we generated two lines of transgenic mice
expressing the mutated form of human MFN2R94Q specifically in
neurons under the control of a neuron specific enolase promoter.
This mutation was selected since the arginine at position 94 has
been reported to be the most commonly mutated residue in
CMT2A patients (Cartoni and Martinou, 2009). As a control, we
generated a transgenic mouse expressing wild-type MFN2 also
under the control of the neuron specific enolase promoter. Here,
we describe the phenotype of these mice and report that
MFN2R94Q transgenic mice display clinical and pathophysiological
symptoms that closely mimic those seen in patients suffering from
CMT2A.
Materials and methods
Generation of transgenic
MitoCharc mice
This work was approved by the Health Department of the State of
Geneva. All experiments were carried out accordingly to good practice
of handling laboratory animals. The R94Q amino acid substitution was
introduced by site-directed mutagenesis (QuickChange, Site-Directed
Mutagenesis Kit, Stratagene) using the human MFN2 cDNA as tem-
plate (hMFN2). We sub-cloned the human MFN2 R94Q cDNA into
the neuron specific enolase promoter-Bcl2 plasmid (Martinou et al.,
1994) using the EcoR1 restriction site to obtain the neuron specific
enolase promoter-MFN2R94Q construct. The neuron specific enolase
promoter-hMFN2R94Q plasmid was linearized with Kpn1 and Xba1,
purified and microinjected into the male pronucleus of B6D2F1 mouse
fertilized oocytes. Genotyping of founder mice was done using MFN2
primers described previously (Cartoni et al., 2005). The same proced-
ure was followed to generate the hMFN2Wt mouse line.
Transgene expression analysis
Detection of transgene expression was done using reverse transcript-
ase polymerase chain reaction (PCR). RNA from tissues was extracted
using TRI Reagent (Sigma) according to the manufacturer’s instruc-
tions. One microgram of RNA was treated with RQ1 DNase
(Promega) for 1 h and transformed into cDNA using M-MLV reverse
transcriptase enzyme (Sigma) and random hexamer primers
(Microsynth, CH). PCR was run on 200–500 ng of cDNA using
human specific MFN2 primers: forward, 50-TGATGGGCTAC
AATGACCAG-30; reverse, 50-AGCTTCTCGCTGGCATGC-30. Relative
quantification of human MFN2 was performed by real time PCR
using the ABI Prism 7500 real-time PCR system and SYBR Green
(Applied Biosystems). All primers were designed to prevent amplifica-
tion of genomic DNA. Cycling conditions were 95C for 10 min, fol-
lowed by 40 cycles of 95C for 15 s and 60C for 1 min. Quantification
was performed using a standard curve established from a serial dilution
of a mix of the samples. Results were normalized using the reference
genes Gapdh (forward: 50-ATCACCATCTTCCAGGAGCG-30; reverse:
50-GGCCTCACCCCATTTGATGT-30). The histogram represents the re-
sults of technical triplicates. For each genotype, cDNAs of at least two
individuals were pooled. To determine the expression of the transgene
relative to the mouse endogenous MFN2 expression, we performed
PCR on cDNA, prepared as described earlier, using primers sharing
complete sequence identity between mouse and human Mfn2.
Forward, 50-GAGCAGCTGGGGGCCTACATCCA-30; reverse, 50-CATT
GATCACGGTGCTCTTCCCATTGCTCG-30. The resulting 214 base
pair PCR product was digested with XmnI enzyme specifically cutting
the human PCR product into two fragments of 122 and 92 base pairs.
Band intensity was measured using ImageJ software.
Behavioural tests
All animals were tested during the light phase of the light-dark cycle.
All the experiments started at 2 p.m., after a 2 h habituation period
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during which mice were placed in the testing room. When possible,
transgenic mice were compared with their littermates. Isolated mice or
pregnant females were excluded. Experiments were run blind. For the
constant speed rotarod test (ROTA-ROD for mice 7650, Ugo Basile,
Varese, Italy), mice were placed on the rotating rod spinning at a
constant speed of 16 rpm. This speed was determined as the average
latency reached by transgenic animals during preliminary accelerating
rotarod tests. The latency to fall was measured individually. Each
mouse performed three times and mice that reached 300 s were
stopped.
The number of mice used for the mutant transgenic lines by age
(1.5, 3 and 5 months) was: MitoCharc1, n= 10, 12 and 11;
non-transgenic, n= 9, 8 and 8; MitoCharc2, n= 7, 7 and 7;
non-transgenic, n= 8, 8 and 8. MitoCharc0 (5, 7 and 10 months):
non-transgenic, n= 6, 6 and 6; MitoCharc0, n= 8, 8 and 8.
For the hind print test, non-toxic black paint was applied on the
inside of the hind paws of the mice. Mice were placed on a paper
sheet at the beginning of a narrow corridor (10 cm  50 cm) and
allowed to complete at least five complete steps.
Electron microscopy
Mice were perfused with 2% paraformaldehyde and 2% glutaralde-
hyde in 0.1 M cacodylate buffer (pH 7.3) for 5 min. The distal part of
the sciatic nerve was dissected and post fixed by immersion in the
fixative solution (2% paraformaldehyde, 2% glutaraldehyde, 0.1 M
cacodylate buffer at pH 7.3) for 2 h at 4C, and washed in 0.1 M
cacodylate buffer, and osmicated for 4 h in 1% OsO4 (Fluka).
Nerves were rinsed in 0.1 M cacodylate buffer, dehydrated and
embedded in epoxy 812-Araldite (Polysciences). Ultra-thin sections
were subsequently cut, collected on cellodin-coated single slot grids
and stained with uranyl acetate and lead citrate. Photographs were
obtained using a Technai G2 electron microscope.
Morphometric analysis
Semi-thin (0.5 mm) nerve cross-sections were stained with 1%
toluidine blue and digitalized using the AxioVision release 4.5 software
(Zeiss). For each myelinated axon present, both an axonal
area (defined by the inner limit of the myelin sheath) and a total
fibre area (defined by the outer limit of the myelin sheath) were
automatically measured using homemade image analysis software
(Arnaud et al., 2009). The g-ratio was calculated by dividing
the axon area by total fibre area. The number of mice used were as
follows: (i) 1.5 months: non-transgenic, n= 4, 6950 axons;
MitoCharc1, n= 4, 7148 axons; (ii) 12 months: non-transgenic,
n = 5, 2716 axons; MitoCharc1, n= 5, 3250 axons; (iii) 12 months:
non-transgenic, n= 4, 3784 axons; MitoCharc2, n= 3 3669
axons. Axonal density was measured from semi-thin nerve cross-
sections used to determine axonal size of 12-month-old animals.
Axonal area was set using ImageJ software and the number of
axons was counted manually. The number of mice used was as
follows: MitoCharc1, n= 3; non-transgenic, n= 3; MitoCharc2, n= 3;
non-transgenic, n= 4.
Mitochondrial analysis
Axonal content of mitochondria was determined blind using electron
microscopy pictures of axons. The number of structures identified as
mitochondria as well as their integrity was determined for each
sample. Individual axon size was measured using Freehand line tool
of ImageJ software on the same electron microscopy pictures used for
mitochondrial content evaluation allowing direct correlation of axonal
diameter and mitochondrial content for each axon study.
The number of axons randomly considered (100 for each mouse)
was sufficient to have the same proportion of small and big axons
between transgenic and non-transgenic control. The number of
mice used was as follows: (i) 1.5 months: MitoCharc1, n= 4; non-
transgenic, n= 4; (ii) 12 months: MitoCharc1, n= 3; non-transgenic,
n= 4; (iii) 12 months: MitoCharc2, n= 3; non-transgenic, n= 4.
Cerebellum histology
Mice were perfused as described in electron microscopy methods.
Whole brain was dissected, embedded in Optimal Cutting
Temperature compound (Tissue-Tek, Sakura) and immediately frozen
in cold isopentane. Sagittal cryosections (10mm) were stained with
haematoxylin and eosin using standard procedures. For immunostain-
ing, specimens were hybridized with anti-calbindin antibody (rabbit
anti-Calbindin D-28k, CB-38a, Swant) following the procedure
of the manufacturer. Briefly, anti-calbindin antibody (dilution
1:1000) was incubated 48 h, followed by 1 h incubation of bio-
tinylated anti-rabbit IgG (H & L) (Vector, dilution 1:200) and 1 h
Streptavidin, Alexa Fluor 594 conjugate antibody (Molecular Probe,
dilution 1:200).
Compound action potential recording
Mice were anaesthetized with Isofluran (Baxter) and beheaded. Sciatic
nerves were dissected and placed in artificial cerebrospinal fluid com-
posed of (in mM) : NaCl, 126; KCl, 3; NaH2PO4, 1.25; CaCl2, 2;
MgCl2, 2; NaHCO3, 26; glucose, 10; pH 7.4 (all salts from VWR),
and continuously bubbled with carboxygen, a 95/5% mixture of
O2/CO2. Nerves were allowed to equilibrate for 60 min before elec-
trophysiological measurement.
For recordings, nerves were transferred to a homemade chamber
perfused with artificial cerebrospinal fluid. Electrical stimuli were
applied using a suction electrode at the proximal end of the
nerve, and compound action potentials were recorded at the distal
end with a pipette filled with artificial cerebrospinal fluid using a
Multiclamp 700B amplifier (Molecular Devices). Signals were filtered
and digitized with a Digidata 1440A (Molecular Devices). We used
pClamp 10 for protocol generation, data acquisition and analysis.
Nerve isolation and recordings were done at room temperature
(20–22C). For each component, we normalized the area by the amp-
litude to minimize the variability between experiments intrinsic to this
technique (Stys et al., 1991) and to differentiate the shape of the
components. Number of mice used from 12 to 14 months:
non-transgenic, n= 10, 15 nerves; MitoCharc1, n= 6, 10 nerves. All
data are presented as mean  SEM.
Statistics
For statistical analyses, we used a standard software package
(R statistical software version 2.9.2). The effect of the rotarod task
on the genotype was evaluated by means of repeated measurement
analysis of variance (ANOVA). Mitochondria number data and axon
size data were evaluated by Poisson and logistic regression, respect-
ively. Compound action potentials were compared using unpaired
Student’s t-test.
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Results
Generation of transgenic mice
over-expressing human MFN2R94Q
cDNA specifically in neurons
Whereas multiple forms of the demyelinating CMT disease (CMT1
and CMT4) have been investigated in detail through generations
of several appropriate animal models (Scherer and Wrabetz,
2008), fewer studies have been devoted to the axonal form
(CMT2). To generate a CMT2A mouse model, the human
MFN2R94Q cDNA (hMFN2R94Q) or wild-type cDNA (hMFN2Wt)
was cloned downstream to the neuron specific enolase promoter
to ensure a pan-neuronal expression of the transgenic cDNA
(Fig. 1A). This promoter was previously found to be selectively
active in neurons of the peripheral and central nervous system,
including motoneurons and dorsal root sensory ganglia, starting at
E13 (Forss-Petter et al., 1990; Martinou et al., 1994). Using clas-
sical transgenic techniques, we obtained two lines that carried the
neuron specific enolase-hMFN2R94Q transgene (hMFN2R94QL51,
hMFN2R94QL87) and one carrying the neuron specific
enolase-hMFN2Wt transgene (hMFN2WtL916). These three lines
bred and produced offspring at the expected frequencies. Mutant
and wild-type MFN2 did not bear any protein tag to avoid alter-
ation of their function. To assess transgene expression in the dif-
ferent lines we rather took advantage of the difference between
human and mouse Mfn2 nucleotide sequences. Using human
MFN2 specific primers, reverse transcription PCR (RT-PCR)
analysis showed that the three transgenic lines expressed the
transgene selectively in neuronal tissues, including lumbar spinal
cord and dorsal root sensory ganglia (Fig. 1B). We named the
mutant line hMFN2R94QL51 MitoCharc1. Because the mutant
line hMFN2R94QL87, heterozygous for the transgene, did not
show any pathological phenotype (data not shown), transgenic
mice from this line were bred to obtain homozygous animals.
We named this homozygous MFN2R94QL87 line MitoCharc2.
The transgenic line hMFN2WtL916 was called MitoCharc0. To
evaluate the expression level of the hMFN2R94Q transgene in
comparison to endogenous Mfn2 in MitoCharc1 and 2 mice, we
used a semi-quantitative RT-PCR approach. Primers sharing
identical sequence between mouse and human MFN2 transcripts
were used to obtain reverse transcriptase polymerase chain reac-
tion products from dorsal root ganglion and spinal cord of trans-
genic mice. A digestion with XmnI generated two bands of 122
and 92 bp from amplicons derived from human MFN2, while
amplicons derived from mouse Mfn2 remained intact (band of
214 bp, Fig. 1C and D). Quantification of these results revealed
a moderate level of transgene overexpression varying from 1.1 to
4.6 times as compared with endogenous Mfn2 expression
(Supplementary Fig. 1A). To compare the level of expression of
the hMFN2R94Q and the wild-type transgene in the correspond-
ing transgenic lines, we also performed quantitative real time
RT-PCR using human specific MFN2 primers. Importantly, the
MitoCharc0 line revealed a level of expression higher than the
level in the two mutant lines making it a good control line to
Figure 1 Generation of MitoCharc mice. (A) Schematic representation of the construct used to generate MitoCharc mice. Human cDNAs
containing either wild-type or the mutated form of MFN2 (R94Q) were cloned downstream to the neuron specific enolase promoter
(NSEp) to ensure a neuron specific expression of the transgene. (B) Transgene expression was measured by reverse transcriptase (RT)
PCR using human specific MFN2 primers. Reverse transcription was performed on RNA extracts from several tissues isolated from
hMfn2R94QL51, hMfn2R94QL87 and hMfn2Wt mice (-RT samples are controls where no reverse transcriptase was added). All lines
expressed the transgene in neuronal tissues. (C and D) Transgene expression relative to endogenous Mfn2. The human MFN2 reverse
transcriptase PCR product (214 bp) is specifically cut by XmnI digestion leading to the detection of two lower bands of 122 and 92 bp.
(C) The first panel shows the complete digestion of the human MFN2 PCR product obtained from the plasmid neuron specific
enolase-hMFN2R94Q, and the absence of digestion fragments in reverse transcriptase PCR products from spinal cord of the
non-transgenic (Non-Tg) mouse (second panel). (D) XmnI digestion of reverse transcriptase PCR product from the indicated tissue
of MitoCharc1, 2 and 0 mice. All the lines showed a moderate level of expression of the transgene.
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evaluate the effect of wild-type MFN2 overexpression in neurons
(Supplementary Fig. 1B).
MitoCharc mice as a model of CMT2A
The first symptoms of patients with MFN2-related CMT2A are
locomotor impairments such as difficulty in walking and frequent
falls (Verhoeven et al., 2006). We therefore tested the motor
capacities of MitoCharc mice using a rotarod test (Fig. 2A).
Whereas we could not detect any difference between mutant
and control animals at 1.5 and 3 months of age, at 5 months of
age both MitoCharc1 and 2 mice performed less well compared to
control non-transgenic littermates and age-matched controls
(P = 0.0082 and 0.0084, respectively). The progressive aspect of
this phenotype was confirmed by a significant difference when
comparing the performance at 1.5 versus 5 months in the two
mutant lines (MitoCharc1 P50.001 and MitoCharc2 P= 0.001).
Interestingly, while MitoCharc1 mice displayed a quite homoge-
neous phenotype at 5 months of age there was a substantial
phenotypic variation among the MitoCharc2 mice (Fig. 2A).
These data suggest a non-complete phenotypic penetrance in
MitoCharc2 mice. By 5 months of age, some animals from the
MitoCharc2 line developed a very striking motor deficit. As de-
picted in Fig. 2B (left panel), they stood very low on their legs and
displayed a dragging tail. This position induced a gait defect as
shown in Fig. 2B (right panel) in a representative hind print test.
Affected MitoCharc2 mice walked with shorter steps and with
everted paws. Thus, although MitoCharc1 and 2 lines showed
similar rotarod impairments, their neurological phenotype was
not identical, probably because of the different transgene expres-
sion levels (Supplementary Fig. 1). Importantly, the MitoCharc0
transgenic mice did not show any phenotype in the rotarod test,
strongly suggesting that the observed phenotype in MitoCharc1
and 2 is a consequence of the expression of the R94Q mutated
form of MFN2 in these animals (Supplementary Fig. 2). Because
cerebellum degeneration has been reported in Mfn2 null mice
(Chen et al., 2007), we investigated its integrity in MitoCharc1
mice. Consistent with the lack of ataxic phenotype in both
MitoCharc1 and 2 mice, we did not observe any morphological
defects of the cerebellum in transgenic animals when compared to
Figure 2 CMT2A-like phenotype in MitoCharc1 and 2 mice. (A) Constant speed rotarod test results of adult MitoCharc1, 2 and their
wild-type littermate and non-transgenic (Non-Tg) controls, respectively. From 5 months of age, MitoCharc1 and 2 mice show marked
locomotor defects. The mean of three trials is represented for each individual mouse. (B) Adult diseased MitoCharc2 mice displayed a
phenotype characterized by a low body position and a dragging tail (left panels). The right panels show a representative hind print test
depicting a gait defect at the same age. Diseased MitoCharc2 mice walked with shorter steps and everted paws. Statistically significant
differences are indicated by **P50.01. Error bars = SEM.
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non-transgenic controls. Molecular, Purkinje and granular layers
displayed a normal appearance (Supplementary Fig. 3).
Increased number of mitochondria in the
peripheral nervous system axons of
MitoCharc mutant mice
While the number of mitochondria is increased in distal axons of
patients with CMT2A (Verhoeven et al., 2006; Vallat et al., 2008;
Funalot et al., 2009), this abnormality has not been observed in
the previously reported in vivo or in vitro models of CMT2A
(Baloh et al., 2007; Detmer et al., 2008). Since MFN2 plays a
role in mitochondrial fusion (Chen et al., 2003), we evaluated
the morphology and distribution of mitochondria in the soma of
motoneurons and axons of the sciatic nerve by electron micros-
copy. We could not detect any morphological abnormality or ag-
gregation of mitochondria in motoneuron cell bodies of 1-year-old
MitoCharc1 mice (Supplementary Fig. 4). In contrast, we observed
that in the medium and small myelinated axons (diameter
53.5mm) of both MitoCharc1 and 2 mice, the number of mito-
chondria per axon, as compared to controls, was significantly
increased (34%, P= 0.007 and 28%, P= 0.011, respectively;
Fig. 3A and B). The number of mitochondria per axon did not
change in larger myelinated axons (diameter 43.5 mm) in either
mutant line. Mitochondrial ultrastructure, as analysed by electron
microscopy, was not different in large or small axons in the sciatic
nerve of MitoCharc1 and 2 mice when compared with their re-
spective controls (data not shown).
In order to assess whether the increased number of mitochon-
dria correlated with locomotor impairments, we also analysed sci-
atic nerves from asymptomatic, 1.5-month-old MitoCharc1 mice.
Interestingly, the number of mitochondria in axons of these mice
was not different from the number of mitochondria in axons of
control non-transgenic littermates (Fig. 3A and B, left panels) sug-
gesting a link between accumulation of mitochondria and the
motor phenotype displayed by older mutant animals.
Axonal calibre defect in the distal part of
sciatic nerves from MitoCharc mice
To investigate further the possible relation between increased
mitochondrial number in the axons and the appearance of loco-
motor defects in older mutant animals, we analysed in detail the
axonal morphology in sciatic nerves from 12-month-old transgenic
and control mice. No major axonal or Schwann cell degeneration
pattern was observed in either genotype at the light microscopic
level (Fig. 4A). Consistent with the axonal neuropathy phenotype
displayed by CMT2A patients, the g-ratio measuring the size ratio
between area of axoplasm and myelin sheath was similar between
MitoCharc1 and 2 mice, and respective controls demonstrating
preservation of normal myelin thickness in mutant animals
(Fig. 4B). The axonal density was also normal in transgenic mice
indicating no gross axonal degeneration (Supplementary Fig. 5).
Since especially late onset CMT2A patients do not necessarily
display gross axonal degeneration (Chung et al., 2006), we inves-
tigated the sciatic nerve axonal morphology in more detail. We
performed a morphometric analysis of axons in the distal part of
the sciatic nerves from MitoCharc1 and 2 mice (Fig. 4C). In
1.5-month-old asymptomatic MitoCharc1 mice, we did not
detect any change in axonal distribution as compared to their
control non-transgenic littermates. However, we observed a
40% (P50.001) and 55% (P50.001) increase in the proportion
of small and medium sized axons and a consequent decrease in
the proportion of larger axons in 12-month-old MitoCharc1 and 2
animals, respectively. Importantly, the switch of the axonal distri-
bution curve of 12-month-old MitoCharc mice occurred approxi-
mately at the axonal diameter of 3.5 mm that corresponds to the
cut-off size under which we detected axonal mitochondrial accu-
mulation (Fig. 3). We then tested whether the increase in the
proportion of small–medium axons in the sciatic nerves of
MitoCharc1 could be confirmed functionally by means of electro-
physiological measurements. We measured sciatic nerve A fibre
compound action potentials (Stys et al., 1991) in 12- to
16-month-old non-transgenic control and MitoCharc1 animals.
As previously described, we were able to generate a fast and
large response corresponding essentially to large diameter A/b
fibres as well as a delayed, small peak corresponding mainly to
A fibres (Supplementary Fig. 6) (Waxman et al., 1995). We
observed a slight non-significant decrease in A/b component
area (Supplementary Table 1A) in the sciatic nerves of
MitoCharc1 mice related to a similar change in their amplitude.
The ratio area/amplitude, the decay slope, and the length of the
A/b response in MitoCharc1 were normal (Fig. 4D, left panel and
Supplementary Table 1). Interestingly, the A fibres component
was altered in the sciatic nerves of MitoCharc1. Compound
action potential amplitude was stable but its average area aug-
mented. The area/amplitude ratio increased significantly suggest-
ing a change in the shape of the A component (Fig. 4D, right
panel). Accordingly, we observed a significant slow down of the
decay (Supplementary Table 1B) that can be correlated to the
change in area. It is likely that this higher area and the slow
down of the A component are due to an increase in the
number of A-like fibres.
Discussion
In this report, we describe the generation and characterization of a
mouse model of the CMT2A peripheral neuropathy induced by a
R94Q mutation in MFN2. We propose that the motor defects
observed in MitoCharc mutant mice are related to the altered
axonal mitochondrial density that may underlie changes in
axonal size distribution.
In previous attempts to build murine models of CMT2A, over-
expression of mutant MFN2 led to an accumulation of mitochon-
dria in the soma of motoneurons and, consequently, to a depletion
of these organelles in axons (Detmer et al., 2008). This altered
cellular topology of mitochondria was probably not linked to the
nature of the MFN2 mutations that were used in these studies but
rather to the expression of a high level of the MFN2 protein.
Indeed, an alteration in the cellular topology of mitochondria,
with aggregation of mitochondria around the nucleus, has also
been observed when wild-type or mutant forms of MFN2 or
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MFN1 were highly expressed in cultured cells (Eura et al., 2003).
In our studies, we did not observe an axonal depletion of mito-
chondria, probably because the level of transgene expression con-
ferred by the neuron specific enolase promoter is moderate (1.1-
to 4.6-fold overexpression) and relatively close to the expected
expression level of mutant MFN2 in neurons from human patients.
Rather, the number of mitochondria in axons of the sciatic nerve
was increased by 30% in mice expressing mutant MFN2. This
observation is consistent with the ultrastructural analysis of the
sural nerve in patients with CMT2A that also revealed an accu-
mulation of axonal mitochondria (Verhoeven et al., 2006; Vallat
et al., 2008; Funalot et al., 2009). To our knowledge, this is the
first time that this key feature of CMT2A, due to an MFN2 mu-
tation, is observed in a mouse model. The increase in mitochon-
drial density observed in the distal axons of MitoCharc mutant
mice, as well as in patients with CMT2A, can have several origins,
including a defect in the retrograde transport of mitochondria, an
increase in the total number of mitochondria or a raise in the
number of the fission events leading to an increased number of
organelles without affecting the total mitochondrial mass. Because
MFN2 is known to play a role in the fusion of the outer mito-
chondrial membrane and mitofusins are required for mitochondrial
Figure 3 Increased number of mitochondria in the distal part of the sciatic nerve from MitoCharc1 and 2 mice. (A) Mitochondria axonal
content was quantified by electron microscopy analysis of distal cross sections of sciatic nerve. At 12 months of age, MitoCharc1 and 2
mice showed an increase in the number of mitochondria in axons with diameter smaller than 3.5 mm. Asymptomatic MitoCharc1 mice
(1.5 months old) did not show any change in the mitochondrial pattern. (B) Quantification of the relative number of mitochondria per
axon in MitoCharc and non-transgenic (Non-Tg) mice. In small–medium axons of 12-month-old MitoCharc1 and 2 mice, the number of
mitochondria was significantly increased by 34 and 28%, respectively. Error bars = SEM, statistically significant differences are indicated by
*P50.05 and **P50.01.
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Figure 4 Axonopathy in the peripheral nervous system of MitoCharc1 and 2 mice. (A) Semi-thin cross sections of MitoCharc1 and
non-transgenic (Non-Tg) sciatic nerves stained with toluidine blue. (B) g-ratio analysis of 12-month-old MitoCharc mice. As revealed by
identical g-ratios between transgenic and non-transgenic animals no myelinization defect was observed in MitoCharc1 and 2 mice.
Number of animals (n) and number of axons measured are the same as in C. (C) Morphometric analysis of axons from MitoCharc1 and 2
mice as compared to non-transgenic controls. At 1.5 months of age, no difference was observed between the axonal repartition of
MitoCharc1 mice as compared to non-transgenic controls (upper panel). At 12 months of age, the axonal distribution pattern revealed
an over representation of small–medium axons (53.5 mm) in both MitoCharc1 (middle panel) and MitoCharc2 (lower panel) mice.
The proportion of small–medium axons was increased by 40 and 55% in MitoCharc1 and MitoCharc2 mice, respectively. (D)
Electrophysiological analysis of MitoCharc1 and non-transgenic control sciatic nerves. The component area/amplitude ratio generated by
the large Ab (left panel) and small–medium fibres A (right panel) showed a significant increase in A component ratio of MitoCharc1
mice. Statistically significant differences are indicated by *P50.05 and ***P50.001.
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fusion, we favour the hypothesis of a mitochondrial fusion defect,
even though an impairment of mitochondrial motility cannot be
excluded. In support of this hypothesis, MFN2R94Q has been
shown to be non-functional for fusion in a context where MFN1
cannot complement the fusion activity (Detmer and Chan, 2007a).
Moreover, neurons express less MFN1 than MFN2 (for example
Purkinje cells or dorsal root ganglion neurons), which makes mito-
chondria in these cells more vulnerable to MFN2 mutations
(Detmer and Chan, 2007a; R. Cartoni, unpublished observation).
Another aspect of the phenotype that distinguishes the
MFN2R94Q transgenic mice from previously published models is
the relatively late onset of their neuropathy. Both at the functional
level (rotarod and gait defects) and at the histological level (axonal
accumulation of mitochondria and shift in axonal size distribution),
only MitoCharc mice 5 months of age became symptomatic.
These data, together with the absence of prominent muscle
atrophy, therefore suggest that MitoCharc1 and 2 transgenic
mice represent a model of a late onset CMT2A (Chung et al.,
2006). Finally, in the MitoCharc1 and 2 mice the neuron specific
enolase promoter is active from embryogenesis until adulthood
whereas in the published model by Detmer et al. (2008), the
HB9 motoneuron-specific promoter is only active until the
post-natal period (P6), which could explain an acute effect on
motoneuron development. The sciatic nerves from MitoCharc1
and 2 mice display an over representation of small calibre axons
in aged animals. Because compound action potential area is pro-
portional to the number of activated fibres and to the square of
their diameters (Keynes and Aidley, 2001), we used compound
action potential recordings on sciatic nerve explants to test
whether the increased proportion of small–medium calibre axons
had an impact on the electrophysiological recordings of the sciatic
nerve. We observed a significant increase of the area/amplitude
ratio for A fibres due to a significant slow down of the decay (Fig.
4D and Supplementary Table 1B). As A component corresponds
to the trace generated by small–medium diameter fibres, these
data corroborate with the increase in the proportion of small
and medium sized axons observed in the sciatic nerves of
MitoCharc1 mice. We did not observe a significant decrease in
Ab component area and amplitude in the sciatic nerve of
MitoCharc1. This is in line with our data from morphometric ana-
lysis, since the largest (A) fibres are the major contributors of the
Ab component and we did not observe any changes in the A
axons of the MitoCharc1. While we did not observe axonal
distribution change at 1.5 months of age (developmental stage
at which the peripheral system already acquired its functional
architecture), the increase in small axonal fibres still may be a
consequence of impaired axonal radial growth since the process
of axonal maturation continues even in older animals (see differ-
ence in axonal distribution at 1.5 and 12 months of age in
Fig. 4C). Alternatively, axonal atrophy of larger axons may also
lead to the observed over representation of smaller axons as pre-
viously suggested in other CMT models (Seburn et al., 2006).
Mitochondrial fission due to disruption of the Mfn2 gene in the
mouse, and consequent dysfunction of these organelles, has pre-
viously been reported to be responsible for neurite atrophy of
Purkinje cells (Chen et al., 2007). This suggests that mitochondrial
fusion impairment could be responsible for the change in the size
of axons in the sciatic nerve of MitoCharc mice. In support of this
hypothesis, the protein affected in autosomal dominant optic
atrophy neuropathy, in which atrophy of the optic nerve is the
main symptom, is optic atrophy 1 (OPA1), a protein responsible
for the fusion of the inner mitochondrial membrane (Alexander
et al., 2000; Delettre et al., 2000; Amati-Bonneau et al., 2009).
Fibroblasts from patients carrying OPA1 mutation display partial or
complete fragmentation of the mitochondrial network suggesting
that mitochondrial network alteration could be the cause of optic
nerve atrophy (Amati-Bonneau et al., 2009). Importantly, similar
to our results in MitoCharc mutant mice, the late onset symptom-
atic CMT2A patients carrying MFN2 mutations do not present any
sign of obvious axonal loss as evaluated in sural nerve biopsies
(Chung et al., 2006). Whether axonal atrophy, as observed in
MitoCharc animals, is present in nerves of late onset CMT2A
patients and if this contributes to their symptomatology remains
to be assessed.
In conclusion, we have generated transgenic mice overexpres-
sing in neurons a mutant or wild-type form of MFN2. Because
only mice expressing mutant MFN2 display clinical symptoms rem-
iniscent of CMT2A, we think that the cause of these symptoms
can unambiguously be assigned to the MFN2R94Q mutation. These
mice represent an interesting tool to further explore the physio-
pathology of CMT2A disease and should make possible the evalu-
ation of future therapeutic approaches.
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